Combined modality therapy.
Encouraging results continue to emerge with the use of chemoradiotherapy. This review of the current literature demonstrates some of the advances that have been achieved in a variety of common malignancies with strategies based on well-defined rationales. Preliminary randomized trials now reveal a survival advantage for chemoradiotherapy in patients with inoperable non-small cell lung cancer and patients with rectal cancer at high risk for recurrence following resection. Other studies report that concurrent chemoradiotherapy may improve local control in patients with limited-stage, small cell lung cancer or esophageal malignancies. The additional toxicity of these approaches is discussed.
McGinn
C J
CJ
Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison 53792.
Kinsella
T J
TJ
D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000628:therapy; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy; D009369:Neoplasms / Q000628:therapy*; D012004:Rectal Neoplasms / Q000628:therapy